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FoxP3, a lineage-specification factor, executes its
multiple activities mostly through transcriptional
regulation of target genes. We identified an inter-
leukin-10 (IL-10)-producing FoxP3+ T regulatory cell
population that contributes to IL-10-dependent
type 2 cytokine bias in breast-cancer patients.
Although genetic ablation of FOXP3 inhibited IL10
transcription, genome-wide analysis ruled out its
role as a transcription factor for IL10. In-depth
analysis revealed that histone acetyl transterase-1,
in association with FoxP3, modified the IL10 pro-
moter epigenetically, making a space for docking
STAT3-FoxP3 complexes. A predictive docking
module with target-receptor specificity, along
with exon-deletion and site-directed mutagenesis
studies, showed that STAT3 binds through its
N-terminal floppy domain to the exon 2 b sheet
region of FoxP3 to form STAT3-FoxP3 complexes.
Such cotranscriptional activity of FoxP3 extended
to other STAT3-target genes that lack FoxP3-binding
sites. These results suggest a function of FoxP3,
where, failing to achieve direct promoter occupancy,
FoxP3 promotes transcription in association with the
locus-specific transcription factor STAT3.
INTRODUCTION
The regulatory T (Treg) cell lineage is indispensable for induction
of T cell tolerance, which is one of the mechanisms of tumor im-
mune evasion (Motz and Coukos, 2013). After tumor growth,
expansion of Treg cells suppresses the activity of tumor-specific
T effector cells (Pandiyan et al., 2007). The X chromosome-
encoded transcription factor FoxP3 is a lineage-specification
factor required for Treg cell differentiation and function (Rams-
dell, 2003), which executes its multiple activities mostly through
transcriptional regulation of its target genes (Zheng et al., 2007).
Continuous expression of FoxP3 in mature Treg cells is required
for the maintenance of suppressor function and FoxP3-depen-
dent transcriptional program (Williams and Rudensky, 2007).ImmGenome-wide analysis of FoxP3-binding sites coupled to
gene-expression profiling suggests that FoxP3 can act as both
a transcriptional activator and a repressor (Marson et al.,
2007). For example, binding of FoxP3 to the 50 regulatory regions
of CTLA4 and IL2RA results in their activation, whereas binding
of FoxP3 to the IL2 and IL7RA promoters facilitates their repres-
sion (Zheng et al., 2007; Gavin et al., 2007). FoxP3 interacts with
retinoic acid receptor-related orphan receptor-a (ROR-a) to
inhibit its transcriptional activity (Du et al., 2008). The dual activity
of FoxP3 defines characteristic features of Treg cells that have
high expression of CTLA4 and CD25 but low expression of IL-
7R and lack IL-2 production.
At least two general subsets of Treg cells exist, natural (nTreg)
and induced or adaptive (iTreg) Treg cells, which seem to differ in
their developments and mechanisms of action (Platten et al.,
2009; Lee et al., 2009). A third subset, represented by T regula-
tory type 1 (Tr1) cells, is the best-characterized adaptive Treg
cells that induce immune suppression in a cytokine-dependent
manner via abundant production of interleukin-10 (IL-10) (Groux,
2003). FoxP3 is a defining feature of nTreg cells that in particular
initiates and supports differentiation and maintenance of this
lineage (Ramsdell, 2003). Meanwhile, recent studies have
demonstrated induction of FoxP3 expression in iTreg cells (May-
nard et al., 2007; Cobbold et al., 2004). Specifically, FoxP3-
expressing iTreg cells that produce IL-10, a lineage distinct
from FoxP3-negative IL-10-producing Tr1 cells, are character-
ized in intestinal and lymphoid tissues (Maynard et al., 2007).
Studies have demonstrated that cancer patients have a preva-
lence of Treg cells in both peripheral blood and tumor micro-
environments (Motz and Coukos, 2013), but the presence of
FoxP3+IL-10+ iTreg cells has not been identified in the tumor
bearer.
FoxP3 has been reported to engage in multiple protein-protein
interactions for establishment of the FoxP3-dependent tran-
scriptional program. Direct interaction of FoxP3 with the tran-
scription factor NFATC2 is required for FoxP3 to bind to a
proximal site in the Il2 promoter in vivo, upregulate several
Treg cell-associated markers, and inhibit IL-2 production (Wu
et al., 2006). Interaction of FoxP3 with the transcription factor
AML1 and Runx1 suppresses IL-2 and interferon-g (IFN-g)
production (Ono et al., 2007). In fact, the amino-terminal region
of FoxP3 contains a ‘‘repressor domain’’ that inhibits Nfatc2
transcriptional activity (Wu et al., 2006). The repressor domain
functions via a direct interaction with the transcriptionalunity 39, 1057–1069, December 12, 2013 ª2013 Elsevier Inc. 1057
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FoxP3 as Cotranscription Factor of STAT3corepressor histone deacetylase-7 (HDAC7) that causes hypoa-
cetylation of histones in the associated chromatin (Li et al., 2007).
Eos, a zinc-finger transcription factor, is similarly a critical
mediator of FoxP3-dependent gene silencing in Treg cells (Pan
et al., 2009). Interestingly, in FoxP3-expressing cells, a greater
number of FoxP3 transcriptional targets are upregulated than
downregulated. However, relatively little is known about the
mechanism by which FoxP3 activates transcription. For
example, apart from a ‘‘repressor domain,’’ the amino-terminal
region of FoxP3 is also required for the upregulation of CD25
and CTLA4 in CD4+ T cells (Wu et al., 2006). FoxP3 binding to
the CD25 and CTLA4 promoters is correlated with hyper-
acetylation of the associated chromatin, suggesting a direct
mechanism of transcriptional activation (Chen et al., 2006). How-
ever, there has hardly been any report on the involvement of
FoxP3 in the transcriptional activation of IL10 in these FoxP3+
IL-10+ iTreg cells.
Signal transducers and activators of transcription (STAT)
factors are found to be associated with molecular signals of
IL-10 expression. Transcriptional activation by STAT proteins
relies on interactions with the coactivator CBP-p300 and re-
quires its histone acetyl transferase activity (Korzus et al.,
1998; Chakravarti et al., 1999). In Treg cells, FoxP3 associates
with the transcriptionally active, phosphorylated form of STAT3
but not with STAT5 (Chaudhry et al., 2009). The contribution of
FoxP3 in transcriptional activation of IL-10 through the recruit-
ment of histone acetyl transterase (HAT) to STAT3, therefore,
cannot be ignored.
Our study describes a population of Tr1-type cells to be
essentially FoxP3 positive, which contributed to IL-10-depen-
dent type 2 cytokine bias in the peripheral circulation of
breast-cancer patients. The lack of FoxP3-responsive elements
in the IL10 promoter abrogated the chances of FoxP3 directly
regulating IL10 transcription. A predictive docking module with
target-receptor specificity along with the exon-deletion mutation
and site-directed mutagenesis revealed that a STAT3 dimer
binds specifically at the exon 2 b sheet region of FoxP3 through
its N-terminal floppy domain to form STAT3-FoxP3 complexes.
Our investigation further demonstrated that FoxP3 acts as a
cotranscription factor that facilitates STAT3-mediated IL10
expression by recruiting HAT1 at IL10 loci. Recruitment of
HAT1modified the IL10 promoter epigenetically, making a space
for docking the STAT3-FoxP3 complexes, thereby enhancing
IL10 gene transcription in Treg cells. This effect of FoxP3 was
extended to other STAT3 target genes, suggesting a cotran-
scriptional mechanism, where failing in direct promoter occu-
pancy, FoxP3 enhanced gene transcription in association with
a locus-specific transcription factor, STAT3. Inhibiting such
cotranscriptional functions of a single target, FoxP3, therefore,
may subsequently impair multiple immunosuppressive proteins,
thereby rejuvenating suppressed antitumor immune responses.
RESULTS
Peripheral TregCells Are EfficientMediators of T Helper
2 Cell Cytokine Bias in Breast-Cancer Patients
For better elucidation of human Treg cells and their associations
with tumor progression parameters, we have used a combina-
tion of phenotypic markers, i.e., expression of FoxP3 and the1058 Immunity 39, 1057–1069, December 12, 2013 ª2013 Elsevier Inphenotypic markers CD25 and CD127, because both regulatory
and activated T cells express CD25. Our immune-phenotyping
studies showed enhanced proportions of CD4+CD25+
CD127FoxP3+ Treg cells and a prevalence of Th2 cell-type
CD4+ T cells in the peripheral circulation of patients with
advanced breast cancer, in comparison to age- and sex-
matched healthy donors (Figures 1A and 1B). Further, a longitu-
dinal assessment of breast-cancer subjects of different stages
showed a significant positive correlation (r = +0.926) between
the percentage of iTreg cells and the type 2 cytokine bias
(Figure 1C) at each stage of breast-cancer development. These
results compelled us to verify the involvement of Treg cells in
tumor-induced type 2 cytokine bias, because a shift from Th1
to Th2 cell-associated cytokine profile and a subsequent lack
of effective cell-mediated immune responses are typical hall-
marks of cancer that often overwhelm the demands of cancer
immune surveillance. However, as a nuclear protein, FoxP3 is
of limited value in the isolation of Treg cells—a major reason
for many functional aspects of Treg cells still remaining obscure.
Hence, CD4+CD25+CD127 Treg cells, characterized as defini-
tive Treg cells, were isolated from the peripheral blood of
breast-cancer patients and cocultured with allogenic CD4+
CD25CD127+ T cells or CD45RA+ naive T cells from healthy
individuals. Indeed, Treg cells from cancer patients were found
to be more efficient mediators of Th2 cell-associated cytokine
bias than were nTreg cells from healthy individuals (Figure 1D).
Additionally, naive T cells, coculturedwith the isolated Treg cells,
not only manifested reduced proliferation but also underwent
apoptosis. These Treg cells quenched the cytotoxic ability of
activated T cells (Figure S1 available online), indicating that these
are definitive Treg cells. In fact, breast-tumor-shed transforming
growth factor-b (TGF-b) augmented high-affinity IL-2Ra (CD25)
on naive CD4+ T cell surface, which harbored IL-2 to induce
FoxP3 expression for generating such tumor Treg cells (see
also Figure S1).
IL-10+FoxP3+ Treg Cells in Tumor Milieu Induce Type 2
Cytokine Bias in an IL-10-Dependent Manner
Earlier studies have reported that FoxP3+ iTreg cells mediate
suppressive effects in vivo mainly through the production of
IL-10 or TGF-b that in turn inhibits cytokine production by Th1
cells, thereby resulting in Th2 cell bias in mucosal immune sys-
tem (Izcue et al., 2006). Our results showed that in peripheral
FoxP3+ Treg cells of breast-cancer patients, IL-10 content was
predominant compared to TGF-b or other cytokines (Figures
1E and S1). Also, the amount of secreted IL-10 in the spent
medium of Treg cells from the breast-cancer patient was signif-
icantly higher than that of TGF-b (Figure S1). Notably, neutraliza-
tion of IL-10 abolished the ability of these Treg cells to induce
type 2 cytokine bias in CD4+CD25 T cells (Figure 1F). These
results substantiated that like Tr1 cells, tumor CD4+CD25+
FoxP3+ Treg cells mediated Th2 cell-type cytokine bias via
IL-10. The mechanism of Treg cell-secreted IL-10-induced Th2
cell bias seems to be fairly heterogeneous and is not fully under-
stood. It has been suggested that IL-10 inhibits Th1 cell prolifer-
ation and cytokine production (Izcue et al., 2006) by interfering
with T cell receptor (TCR) signaling pathways responsible for
Th1 cell-associated cytokine production (Brogdon et al., 2002)
or by regulating a STAT3-induced transcriptional inhibitor thatc.
Figure 1. Tumor-Induced Augmentation of T Regulatory Cells Mediated Type 2 Cytokine Bias
(A) CD4+CD25+CD127FoxP3+ Treg cells in peripheral circulation of breast-cancer patient and normal individual (left). Percent CD4+CD25+CD127 and
CD4+CD25+CD127FoxP3+ Treg cell populations (right).
(B and C) Altered Th1 and Th2 cell-associated cytokine profile (B) and correlation between tumor-associated Treg cell augmentation and Th2 cell-type cytokine
bias at different stages of breast cancer (C).
(D) Th2 cell-associated cytokine bias in naive T cells after coculturing with Treg cells isolated from healthy donors and breast-cancer patients.
(E) IL-10, TGF-b, IL-2, IL-4, and IL-13 positivity in tumor-associated Treg cells.
(F) Th2 cell bias in naive T cells cultured in tumor-associated Treg cell spent media containing control-IgG, IL-10, and TGF-b neutralizing antibodies.
Values are representative or mean ± SEM of five independent experiments. See also Figure S1.
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FoxP3 as Cotranscription Factor of STAT3can selectively control transcription at inflammatory promoters
such as tumor necrosis factor-a (TNF-a) (Akdis and Blaser,
2001). In line with these findings, we observed that when naive
T cells were cocultured with tumor-associated Treg cells, the
proliferative potential of Th1 cells was reduced compared to
Th2 cells. In addition, Treg cells quenched the available IL-2
from the system so that susceptible Th1 cells could not survive
(Figure S1). Hence, the relative bias moved toward Th2 cell
differentiation. All these findings together confirm the presence
of FoxP3+IL-10+ Treg cells in the peripheral blood of breast-
cancer patients, mediating the Th2 type cytokine bias via IL-10.FoxP3 and IL-10 Coexpression Correlates in
CD4+CD25+FoxP3+ Treg Cells
The above-mentioned findings seemed to be contradictory to
numerous studies that demonstrated high expression of IL-10
in FoxP3-negative Treg cells, referred to as Tr1 cells (Groux,
2003), indicating the expendable role of FoxP3 in IL-10 expres-
sion in these FoxP3+ Treg cells from breast-cancer patients.
Therefore, to confirm whether the expression of FoxP3 and
IL-10 were correlated in these Treg cells, we exploited either
Treg cells isolated from a breast-cancer patient’s blood or naiveImmT cells, cultured with supernatants from breast-cancer tissues to
develop into Treg cells. As shown in Figure 2A, there was a
significant positive correlation (r = +0.797) between FoxP3 and
IL-10 expression in Treg cells isolated from the breast-cancer
patient’s blood, indicating that FoxP3 might be involved in
IL-10 expression.Both FoxP3 and STAT3 Are Indispensable for IL10
Transcription in Tumor-Induced Treg Cells
An important question at this point was whether FoxP3 contrib-
utes to IL10 expression in IL-10-producing FoxP3+ Treg cells. To
address this, we measured the amount of IL10 transcripts in
FoxP3-silenced CD4+ T cells in tumor conditions. Our results
revealed that FoxP3 silencing caused a significant reduction in
IL10 transcripts, demonstrating a critical role of FoxP3 in main-
taining IL10 expression in these Treg cells (Figures 2B and 2C).
Our IL10 promoter binding analyses by ChIP via anti-RNA Pol-II
and the above findings suggested that FoxP3 is indispensable
for IL10 transcription in tumor-associated Treg cells. However,
genome-wide analysis of FoxP3-targeted genes by RVISTA
and Matinspector, using Cold Spring Harbor Laboratory pro-
moter database demonstrating the absence of a FoxP3-bindingunity 39, 1057–1069, December 12, 2013 ª2013 Elsevier Inc. 1059
Figure 2. FoxP3 Associates with STAT3 to Drive IL10 Transcription in Tumor-Associated Treg Cells
(A) Scatter plot of MFI values of FoxP3 and IL-10 among Treg cells isolated from different stages of breast cancer. The solid line shows the best line fitted to the
data based on simple regression model.
(B and C) IL-10 protein (B) and IL10mRNA (C, left) were determined in Treg cells developed from FoxP3-shRNA-transduced naive T cells in the presence of tumor
supernatant. ChIP assay for RNA polymerase-II activity at IL10 promoter was carried out under the same cellular conditions;GMPR promoter bindingwas used as
negative control (C, right).
(D) 2D gel electrophoresis pattern of FoxP3-associated proteins (left). MALDI-TOF MS spectrum of tryptic-digested peptides of the protein labeled as spot#1
(right). The identity of the spot#1 is represented in tabular form.
(E) From FoxP3-silenced Treg cell nucleus, FoxP3-associated STAT3 were immunoblotted with specific antibody.
(F) Confocal microscopic images of normal T cells and tumor-associated Treg cells immunostained with Alexa 488- or 546-conjugated pY-STAT3 and FoxP3
antibodies (scale bar represents 2 mm). Histone H1 or GAPDH was used as internal control.
Values are mean ± SEM or representative of five independent experiments. See also Figure S2.
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FoxP3 as Cotranscription Factor of STAT3site at the IL10 promoter, contradicted the possible role of FoxP3
directly regulating IL10 transcription. We therefore hypothesized
that in these cells, FoxP3might be contributing to IL10 transcrip-
tion in cooperation with other transcription factor(s). To explore
this hitherto unknown role of FoxP3, we first tried to identify
the nuclear factors it could be associated with. For this,
FoxP3-associated proteins were immunopurified from the nu-
clear extracts of FoxP3+ Treg cells followed by 2D-gel electro-
phoresis and MALDI-TOF MS analysis. Data in Figure 2D
(Spot#1) indicated the association of FoxP3 with STAT3. Pre-
dicted STRING functional protein association network (STRING
9.05) of FoxP3 also implied a direct physical association be-
tween FoxP3 and STAT3 (Figure S2), which was confirmed by1060 Immunity 39, 1057–1069, December 12, 2013 ª2013 Elsevier Incoimmunoprecipitation and confocal microscopy (Figures 2E
and 2F). All these data support the conclusion that in these
Treg cells, FoxP3 is specifically associated with the tran-
scriptionally active, tyrosine-phosphorylated form of STAT3 in
the nucleus. Moreover, the immunoblot data in Figure 3A
confirmed that along with STAT5, STAT3 was intensely tyro-
sine-phosphorylated in tumor-associated Treg cells. However,
in accord with Benkhart et al. (2000), STAT3, but not STAT5,
was actually required for the induction of IL-10+ Treg cells as it
was also for the IL10 transcription in these cells (Figures 3B
and 3C). Consistent with the involvement of FoxP3, STAT3 was
also indispensable for IL10 transcription as demonstrated by
confocal microscopy (Figure 3D).c.
Figure 3. FoxP3 Augments STAT3-Mediated IL10 Expression in Treg Cells
(A) Immunoblot analysis of all possible (total and tyrosine-phosphorylated) forms of STATs in T cells treated with or without tumor supernatant.
(B and C) Percent IL-10 positivity (B) and amount of IL10 mRNA in STAT3- and STAT5-silenced Treg cells (C).
(D) Confocal images showing intracellular IL-10 in control T cells and STAT3- or FoxP3-silenced tumor-associated Treg cells (scale bar represents 2 mm).
(E) IL10 promoter-binding activity (STAT-binding site) for STAT3 and FoxP3 in Treg cells generated in STAT3- or FoxP3-silenced conditions.
(F) IL10 and CTLA4 mRNA expressions in Treg cells generated in STAT3 or FoxP3-decoy oligonucleotide-transfected conditions.
(G) Endogenous FoxP3-silenced T cells were transfected with shRNA-sensitive (FOXP3WT), shRNA-resistant (FOXP3(shRNAmt)), DNA-binding defective shRNA-
sensitive (FOXP3DFKH+NLS) or -resistant (FOXP3DFKH+NLS(shRNAmt)) clones before tumor-associated Treg cells were generated. IL10-mRNA expression was
determined by qPCR. Histone H1 or GAPDH was used as internal control.
Values are mean ± SEM or representative of five independent experiments. See also Figure S3.
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FoxP3 as Cotranscription Factor of STAT3FoxP3 Functions as a Transcriptional Coactivator of
STAT3 in Tumor-Associated Treg Cells
Next, to prove our hypothesis that FoxP3 and STAT3 interaction
might increase the transcriptional activity of STAT3, we per-
formed IL10 promoter binding studies in tumor-associated
Treg cells. Consistent with the presence of putative STAT-Immresponsive elements at IL10 gene locus (Benkhart et al., 2000),
we observed the binding of STAT3 to the IL10 promoter along
with FoxP3 in these cells (Figure 3E). Notably, although the
IL10 promoter lacks a FoxP3-responsive element, similar to
STAT3 ablation, genetic deletion of FoxP3 also resulted in a
decreased ChIP signal for both STAT3 and FoxP3 on the IL10unity 39, 1057–1069, December 12, 2013 ª2013 Elsevier Inc. 1061
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FoxP3 as Cotranscription Factor of STAT3promoter (Figure 3E). These results compelled us to re-examine
the direct DNA-binding ability of FoxP3. Unlike cells transfected
with STAT3-decoy oligonucleotide, FoxP3-decoy oligonucleo-
tide transfectants continued expressing IL10 at par with un-
transfected cells and FoxP3-decoy efficiently inhibited CTLA4
expression in these cells (Figure 3F). These findings offer the
potential that, though pivotal for IL10 expression, transcriptional
regulation of the IL10 gene is independent of direct promoter
occupancy by FoxP3. Initial proof of the hypothesis came from
the comparative IL10 expression studies in tumor supernatant-
treated naive T cells, transfected with shRNA-resistant
(shRNAmt) mutant FoxP3 clones containing a nuclear localiza-
tion signal (NLS) and in which the DNA-binding motif (FKH)
was deleted (FOXP3DFKH+NLS(shRNAmt)) (see Figure S3 for details).
Results in Figure 3G showed a significant decrease in IL10
transcription in the cells containing shRNA-sensitive
FOXP3DFKH+NLS clone but not in the cells containing shRNA-
resistant FOXP3DFKH+NLS(shRNAmt) clone. Further restoration of
IL10 transcription in the FOXP3DFKH+NLS clone-containing Treg
cells validated an indirect role of FoxP3 in IL10 promoter binding
(Figure 4A, left). Moreover, in a sequence of experiments with
deleted or mutated FOXP3 (Figure S3) and STAT3 clones at
different exons or motifs, the exon 2 motif of FoxP3 and the
N-terminal domain of STAT3 were found to be essential for
IL10 transcription (Figure 4A). This exon 2 motif of FoxP3 was
also identified as the STAT3 interactive domain (Figure 4B).
ChIP-reChIP experiments subsequently demonstrated that
failing to bind directly to DNA, FoxP3 formed a complex with
STAT3 and this FoxP3-STAT3 complex was actually recruited
to the IL10 promoter (Figure 4C).
We obtained a predictive theoretical model by processing
the crystal structures of FoxP3 and STAT3 in the protein prep-
aration wizard, where we found that STAT3 binds specifically
to the exon 2 b sheet region of FoxP3 through its N-terminal
floppy domain to form the STAT3-FoxP3 complex (Figure 4D).
The interaction between the dimeric FoxP3 and the STAT3
dimer induced a certain conformational change that drove
the complex to bind to the chromatin-associated DNA. The
docked complex revealed certain amino acids that are involved
in polar interaction and can be predicted to be the key con-
tacts responsible in forming the complex between FoxP3 and
STAT3 dimers. The side chain carbonyl-oxygen atom of E616
(STAT3) behaved as the acceptor of two H-bonds and inter-
acted with P88 (FoxP3) (2.9A˚ and 3.1A˚ distances); S614
(STAT3) interacted as the H-bond acceptor with P90 of
STAT3 (4.3A˚); and G558 (STAT3) acted as H-bond acceptor
and donor with K85 (3.7A˚) and H91 (2.8A˚), respectively, of
FoxP3. All these are believed to be the key interactions that
stabilize the tetrameric complex. In addition, one more inter-
action was found between P72 and T73 of FoxP3 and is
believed to induce the protein folding necessary for good stea-
ric complex with the STAT3 protein (Figure 4E). The above in-
teractions (less than 4A˚ distance) can thus be considered to
strengthen the complex formed between FoxP3 and STAT3.
Notably, the space-filling model shows that the N-terminal
floppy region of STAT3 perfectly fits into the b sheet region
exon 2 of FoxP3. The predictive docking module also reveals
that the FoxP3 dimer binds to the dimeric-STAT3 and that
such an interaction between FoxP3 and STAT3 induces a1062 Immunity 39, 1057–1069, December 12, 2013 ª2013 Elsevier Inconformational change that drives STAT3 to bind to chro-
matin-associated DNA.
The in silico prediction for the interaction between FoxP3 and
STAT3 was validated through a series of site-directed mutagen-
esis at the P72, T73, K85, P88, P90, and H91 positions of FoxP3
by the single-amino-acid-substitution primer, designed by
Primer X (http://www.bioinformatics.org) and characterized by
Oligoanalyzer (integrated DNA technology). The results depicted
in Figure 4F indicate that alterations of P88 and H91 completely
blocked the interaction between FoxP3 and STAT3, whereas
mutations of P90 and K85 disrupted partially but significantly
this interaction. Meanwhile, P72 and T73, which is believed to
induce necessary protein folding, partially hindered the ability
of FoxP3 to bind to STAT3.
The aforesaid observation from molecular docking calcula-
tions was well correlated with coimmunoprecipitation, deletion
mutation, and confocal microscopy (Figures 2 and 4). Together,
these findings raised the possibility of transcriptional coactivator
activity of FoxP3 during STAT3-mediated IL10 gene regulation.
Localized Chromatin Modification by FoxP3-Associated
HAT1 Induces STAT3-Mediated IL10 Transcription
Next, we attempted to unveil the mechanism supporting the
cotranscriptional role of FoxP3 in regulating the transcriptional
activity of STAT3. Our data in Figure 5A distinctively indicated
that apart from STAT3 (spot#1), FoxP3 was also associated
with HAT1 (spot#3 in Figure 5A). Our coimmunoprecipitation
studies further confirmed the direct association of HAT1 with
FoxP3 in tumor-associated Treg cells (Figure 5B). Because
HAT1 acetylates DNA-bound histone to relax the chromatin
structure as required for accessibility of transcription factors to
their respective DNA-binding sites, we next checked the histone
acetylation status of IL10 promoter region in these cells. Results
(Figure 5C) showed that in FOXP3- or HAT1-silenced cells, the
histone acetylation was decreased significantly in IL10 promoter
region, whereas STAT3 silencing partially reduced the histone
acetylation. FoxP3 was found to be bound to HAT1 and helped
it to translocate from the cytosol into the nucleus (Figures 5D
and 6) where a transient ternary complex was formed with
STAT3 (Figure 5B) that bound the IL10 promoter, resulting in
epigenetic modification. HAT1 acetylated histone H4 at K5 and
K12 residues predominantly and histone H2A at K5 residue
moderately. These modifications led to the opening of the
STAT-responsive element of IL10 promoter, thereby facilitating
the docking of STAT3-FoxP3 complex with consequent tran-
scription of IL10 (Figures 5E and 5F). A similar kind of predictive
docking module with target-receptor specificity study showed
the probable association between dimeric-FoxP3 and HAT1
(Figure 5G). As soon as HAT1 modifies IL10 promoter, a
FoxP3-dimer forms a complex with dimeric-STAT3. The prob-
able competitive phenomenon happens because the FoxP3-
STAT3 complex is formed with an increase of surface area for
a more favorable interaction, as compared to FoxP3-HAT1.
These findings indicate that FoxP3, in association with HAT1,
modifies the IL10 promoter epigenetically, providing a confor-
mational space to the STAT3-FoxP3 complex at its putative
binding site (Figure 6). These results identify FoxP3 as a major
transcription cofactor of STAT3 in mediating the IL10 transcrip-
tion in Treg cells in tumor milieu.c.
Figure 4. STAT3 Binds to Exon 2 b Sheet Region of FoxP3 through Its N-Terminal Floppy Domain
(A) To identify the motifs involved in FoxP3 and STAT3 interaction, T cells were transfected with a series of mutant, exon-deleted FOXP3 (left) and STAT3 (right)
clones (described in Experimental Procedures; see also Figure S3) prior to the generation of tumor-associated Treg cells. Amounts of IL10 mRNA were
determined by qPCR.
(B) FoxP3-associated pY-STAT3 in the nuclear extract was determined by immunoblot in wild-type or exon-deleted FOXP3 transfected tumor-associated
Treg cells.
(C) ChIP re-ChIP studies were carried out to evaluate STAT3-FoxP3-associative binding at IL10 promoter (STAT-binding site).
(D) Structure of the DNA-bound form of FoxP3-STAT3 tetramer (left). The complex furnished was rotated by 90; STAT3, green; FoxP3, cyan; Ex-2 b sheet region
of FoxP3, wheat or red; N-terminal floppy domain of STAT3, N-STAT3 (right).
(E) Possible amino acid residues involved in the interaction between FoxP3 and STAT3 (left). The molecular surface model showed that the N-terminal floppy
region of STAT3 fit perfectly into the Ex-2 b sheet region of FoxP3 (right).
(E) To identify amino acids of FoxP3 involved in FoxP3-STAT3 interaction, T cells were transfected with FOXP3P72M, FOXP3T73V, FOXP3K85E, FOXP3P88M,
FOXP3P90M, or FOXP3H91F clones before the generation of tumor-associated Treg cells and IL10 messages were determined by qPCR. Histone H1 or GAPDH
was used as internal control.
Values are mean ± SEM or representative of five independent experiments.
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Figure 5. FoxP3-Recruited HAT1 Induces Histone Acetylation and Enhances STAT3 Transcription Activity
(A) MALDI-TOF MS (right) analysis of spot#3 obtained after 2D gel electrophoresis (left) for FoxP3-associated proteins is represented in tabular form after the
processed peaks.
(B) FoxP3 and HAT1-associated proteins were immunopurified from the nuclear extract of FoxP3- and STAT3-silenced Treg cells and then immunoblotted with
HAT1 and pY-STAT3 antibodies.
(C) In STAT3, FoxP3, HAT1, or p300 siRNA-transfected conditions, tumor-associated Treg cells were analyzed for histone acetylation pattern of IL10
promoter.
(D) Confocal images of normal T cells and tumor-associated Treg cells immunostained with Alexa 488- or 546-conjugated FoxP3 and HAT1 antibodies (scale bar
represents 2 mm).
(legend continued on next page)
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Figure 6. Schematic Diagram Depicting
Cotranscriptional Activity of FoxP3 in Regu-
lating STAT3-Targeted Genes
A predictive docking module with target-receptor
specificity study showed that FoxP3 dimer binds
HAT1 and brings it into the nucleus to form a
transient ternary complex with the STAT3 dimer.
This complex epigenetically modifies the IL10
promoter, thereby making space for the docking
of the STAT3-FoxP3 complex.
Immunity
FoxP3 as Cotranscription Factor of STAT3Cotranscriptional Activity of FoxP3 Is Not Restricted to
IL10 Expression in Treg Cells
In an attempt to verify whether the cotranscriptional activity of
FoxP3 was applicable to other STAT3-targeted genes in tu-
mor-associated Treg cells, we searched for the same activity
on other STAT3-targeted genes having a role in immune evasion
(Motz andCoukos, 2013). Our qPCR studies revealed that similar
to the STAT3 silencing, a silencing of FoxP3 decreased the
expression of other STAT3-targeted genes such as IL6, VEGFA,
CMYC, BCL2L1, and CCND1, but not TGFb1 (Figure 7A). We
then examined the association between STAT3 and FoxP3 in
the case of these STAT3-targeted genes. As shown in Figure 7B,
similar to the case of IL10, the STAT3-associated FoxP3 was
found to be docked at the promoter regions of IL6, VEGFA,
CMYC, BCL2L1, and CCND1 but not at that of the TGFb1 pro-
moter. To confirm the requirements of both FOXP3 and STAT3
in the expression of these genes, we silenced FoxP3 and
STAT3 in parallel sets of experiments where transfectants were
cultured with tumor supernatants. Confirming our hypothesis,
we observed reductions in the transcripts of IL6, VEGFA,
CMYC, BCL2L1, and CCND1 in both the sets (Figure 7). These
findings further strengthened the previously described role of
FoxP3 as a cotranscriptional factor of STAT3 in Treg cells in
the tumor microenvironment. These studies, essentially unravel-(E) Specific histone acetylation pattern of STAT-binding sites of IL10 promoter was determined by ChIP assa
H4K12 antibodies.
(E) IL10 promoter binding activity of HAT1 in tumor-associated Treg cells was determined by ChIP assay.
(F) Ribbon diagram of FoxP3 dimer on HAT1. Histone H1 was used as internal control.
Values are mean ± SEM or representative of five independent experiments.
Immunity 39, 1057–1069, Deing FoxP3 as a cotranscriptional factor,
necessitate the characterization of mech-
anisms underlying the tumor-induced
augmentation of FoxP3, therapeutic
intervention of which may neutralize
FoxP3-mediated immunosuppression.
DISCUSSION
Therapeutic induction of effective anti-
tumor T cell responses in human cancer
patients requires surmounting diverse
hurdles. Various evidences suggest that
switching over of T cell responses toward
a Th2 cell-associated response is an
important mechanism of immune evasion
in cancer patients and animal models(Lathers et al., 2003; Tatsumi et al., 2002). Such Th2 cell bias
may limit the efficacy of immunotherapeutic approaches. We
found that a FoxP3-positive Treg cell population, isolated from
breast-cancer patients, exhibited a strong Th2 cell phenotype,
producing large amounts of IL-10. In these cells lacking
promoter occupancy, FoxP3 acted as a cotranscription factor
of STAT3. In fact, FoxP3 associated with HAT1, which in turn
modified the IL10 promoter epigenetically through histone acet-
ylation, providing a conformational space to STAT3-FoxP3
complex at the putative binding site of STAT3 on the IL10
promoter. Because FoxP3 is not generally known as a transcrip-
tional coactivator, these results have a bearing on the question of
‘‘conditional’’ gain of function of FoxP3, depending on the
cellular microenvironment.
Earlier studies described the expression of lineage-specific
markers amongCD4+ T effector cell subsets as a stable unidirec-
tional process. However, observations of cells with mixed
phenotypes have raised questions about the stability of helper-
lineage fidelity and the relationships among lineages. For
example, there is now abundant flexibility in terms of cytokine
production (Lee et al., 2009), but perhaps the best model is
IL-10. Initially viewed as a Th2 cell type cytokine, it is now recog-
nized that Th1, Th17, and Treg cells all make IL-10. Similarly,
FoxP3-expressing Treg cells become IL-17 producers, expressy with acetylated histone H2AK5, H4K5, H4K8, and
cember 12, 2013 ª2013 Elsevier Inc. 1065
Figure 7. FoxP3 Silencing Reduces the Expression of Other STAT3-Targeted Genes
Tumor-associated Treg cells generated in FoxP3- or STAT3-silenced conditions were subjected to (A) qPCR to determine relative mRNA expression patterns and
(B) ChIP assay to determine the role of FoxP3 and STAT3 in the promoter binding activity of STAT3-targeted genes IL10, IL6, VEGFA, TGFb1, CMYC, CCND1,
BCL2L1, and GMPR. GAPDH was used as internal control. Values are mean ± SEM of five independent experiments.
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FoxP3 as Cotranscription Factor of STAT3the Th1 cell-associated transcription factor T-bet, or make IFN-g
(Koch et al., 2009). Adding to this knowledge, our study identified
from breast-cancer patients a population of FoxP3+ IL-10-
producing Treg cells, a subtype distinct from FoxP3 IL-10-
producing class 1 Treg cells. It is well reported that the expres-
sion of the lineage-specific DNA-binding factor FoxP3 controls
the development and function of naturally occurring Treg
cells (Ramsdell, 2003). FoxP3 has been shown to interact
with numerous transcriptional regulators including NFAT,
p65NF-kB, Runx1, and RORgt, as well as the histone modifica-
tion enzymes TIP60, HDAC7, and HDAC9 (Loizou et al., 2011). In
fact, FoxP3 regulates transcription of its targets by binding to
their promoters either directly or through interaction with
locus-specific transcription factors and recruits HDACs and
HATs resulting in chromatin remodeling and either cessation or
initiation of transcription, respectively. The sum of these interac-
tions is believed to cause the change in the transcriptional pro-
gram of Treg cells. All such information led us to hypothesize
that FoxP3 is regulating the transcription of IL10 in these
FoxP3+ IL-10-producing Treg cells. However, Treg cells, charac-
terized by their specific expression of FoxP3, do not express1066 Immunity 39, 1057–1069, December 12, 2013 ª2013 Elsevier InIL-10 after stimulation directly after ex vivo isolation, unless
isolated from the gut (Maynard et al., 2007). In addition,
genome-wide analysis failed to identify any binding site for
FoxP3 in the IL10 promoter, although silencing of FoxP3 reduced
IL10 transcription in these cells. These findings fit nowhere in the
aforementioned discussion on the mechanism by which FoxP3
functions as a transcriptional regulator, thereby bringing in
controversy about our proposed model of FoxP3-dependent
regulation of IL10 transcription.
It is acknowledged that STAT3 signaling within the tumor
microenvironment shifts the balance of tumor immunity toward
carcinogenesis (Kortylewski et al., 2009). Activated STAT3
suppresses antitumor immunity by inhibiting the expression of
many cytokines and chemokines important for stimulating anti-
tumor immunity and by upregulating the production of several
immunosuppressive factors including IL-10 and VEGF (Takeda
et al., 1999;Wang et al., 2004). Our efforts to understand the hith-
erto unappreciated role of FoxP3 revealed that in these Treg
cells, FoxP3 was specifically associated with the transcription-
ally active phosphorylated form of STAT3 in the nucleus. The
interaction between dimeric FoxP3 and STAT3 dimer inducedc.
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chromatin-associated DNA. The docked complex as well as
the site-directed mutagenesis study revealed certain amino
acids to be involved in polar interaction (less than 4A˚ distance),
which are key contacts responsible for forming the complex
between FoxP3 and STAT3; this is in conformity with the finding
by Ichiyama et al. (2008) that exon 2 region of FoxP3 was neces-
sary for direct interaction with RORgt to suppress IL17 promoter
activity.
It is now acknowledged that in addition to the transcription
factor binding, a crucial part of gene regulation is the epigenetic
regulation, which includes DNA methylation, ATP-dependent
nucleosome remodeling, and histone modifications (Jaenisch
and Bird, 2003). Acting together with transcription factors, these
chromatin modifications have major effects on gene expression.
Previous reports have revealed that the transcription factor
FoxP3 can dramatically change histonemodifications at its bind-
ing loci and regulate expression of the adjacent genes (Chen
et al., 2006). In that case, FoxP3, having direct promoter occu-
pancy, functions as a scaffolding molecule, which helps in
recruiting the different components of transcriptional machinery
(Chen et al., 2006). Our attempt to explore the role of FoxP3 in
aiding STAT3 binding to the IL10 promoter revealed that besides
STAT3, FoxP3 was associated with HAT1 also in these Treg
cells. On binding to HAT1, FoxP3 brought the latter into the
nucleus to form a transient ternary complex with STAT3.
Because the molecular selectivity of FoxP3 was more biased
toward STAT3 dimer, FoxP3-STAT3 binding freed HAT1, which
then modified the IL10 promoter epigenetically to provide a
conformational space to the STAT3-FoxP3 complex at its puta-
tive binding site. It is interesting to note that like tumor-associ-
ated Treg cells, other T cell subsets such as Th1, Th2, Th17,
and Tr1 cells can also secrete IL-10 via STAT-mediated signaling
(Saraiva and O’Garra, 2010). However, the STAT-responsive
element of the IL10 promoter in these cells remained epigeneti-
cally silenced. So, failing to direct promoter occupancy, STATs
(STAT4 in Th1 cells, STAT6 in Th2 cells, STAT3 in Th17 and
Tr1 cells) induced cMAF, which docked the cMAF-responsive
element of the IL10 promoter to induce IL-10 (data not shown).
In tumor-associated Treg cells, however, FoxP3-associated
HAT1 hyperacetylated histone H2A and H4 of the STAT-respon-
sive element and the IL10 promoter remained demethylated to
make a pocket for STAT3-FoxP3 binding to its cognate site.
The above conclusion, therefore, undoubtedly identifies FoxP3
as a major transcription cofactor of STAT3 in mediating IL10
transcription in Treg cells in the tumor milieu.
Notably, this function of FoxP3 was not restricted to IL10;
rather, it was also effective for other STAT3 target genes. These
findings demonstrate cooperation between two ‘‘transcription
factors’’ during tumor-mediated immunosuppression, where
FoxP3 serves as a cotranscription factor of STAT3. Inversely,
STAT3 dependency of FoxP3+ Treg cell suppressor function
has been previously reported where conditional ablation of
Stat3 allele in FoxP3+ Treg cells normalizes Treg cell-mediated
pathogenic Th17 cell responses (Lu et al., 2010). These results
are supported by Chaudhry et al. (2009) who, in their efforts to
define potential mechanisms of Stat3-dependent regulation of
Treg cell function in Stat3-deficient and -sufficient YFP+ Treg
cells isolated from healthy heterozygous Foxp3Cre/wtStat3fl/flImmand Foxp3Cre/wtStat3fl/wt mice intestine, showed that 20% of
FoxP3-dependent genes were also dependent on STAT3
expression in Treg cells. Moreover, Il10 was one of those genes
implicated in Treg cell suppressor function (Izcue et al., 2006;
Groux, 2003).
To summarize, our findings indicate a gain of function of FoxP3
even in the absence of any mutation in tumor milieu, where, to
support the Treg cell development as well as to maintain the
immunosuppressive environment, the recognized transcription
factor FoxP3 acts as a cotranscription factor of STAT3 to gain
access to the promoter region for tuning the chromatin by
HAT1-induced epigenetic modifications and for providing the
proper environment for transcription of adjacent genes. Mod-
ulation of transcription factor activity may be the critical
consequence of genetic and epigenetic alterations that affect
antitumor immunity. Thus, the description of such cotranscrip-
tional activity of FoxP3 will not only enrich the knowledge of
molecular complexities in the Treg cell plasticity, but also reveal




The present study included 38 female breast-cancer (stage I, n = 8; stage II, n =
12; stage III-IV, n = 18) patients and 21 age- and sex-matched female healthy
volunteers. CD4+ T cells were purified from peripheral blood bymagnetic bead
(Militenyi). Tissues from primary lesions of breast cancer were collected from
patients undergoing surgical procedures. Informed consent (IRB-1382) under
the provision of Human Ethics Committee, Bose Institute (approval No: BIHEC/
2010-11/2), was obtained from all patients with localized disease and healthy
donors compliance with the Helsinki Declaration (http://www.wma.net/en/
30publications/10policies/b3/index.html). Breast-cancer cells from primary
tissue were isolated and cultured in RPMI 1640 media. After 72 hr, superna-
tants were freed from cellular components and were used in 1:1 ratio with
RPMI 1640 media to study the effect of tumor supernatant on T cells. For
T cell polarization, flow cytometrically sorted cord blood CD4+CD45RA+
T cells were activated with anti-CD3 and anti-CD28 beads (Invitrogen) and
allowed to differentiate into different subsets of T cells in the presence of spe-
cific cytokines and/or neutralizing cytokines antibodies (BD Bioscience). Tr1
cells were isolated from the peripheral blood of a hepatitis patient (n = 5).
Flow Cytometry
For the determination of intracellular cytokines, T cells were labeled with
PerCP-CD4 and PE-IFN-g, IL-2, IL-4, and IL-10 antibodies (BD Bioscience).
Treg cells were assayed by labeling with PerCP-CD4, FITC-CD25, APC-
CD127, PE-FoxP3, or APC-FoxP3 antibodies (BD Bioscience). Cell-surface
IL-2 binding was assayed by labeling unfixed Treg cells with PE-IL-2 antibody.
T cell proliferation was determined by CFSE-dilution assay of naive T cells
cocultured (for 3 days) with tumor-derived Treg cells. Treg cell-induced
T cell apoptosis was assayed by Annexin-V and 7AAD positivity. Cells were
analyzed flow cytometrically (BD Bioscience). For the purification of naive
and regulatory T cells, CD4+ cells, labeled for CD25 and CD127, were sub-
jected to high-speed cell sorting (FACS-Aria) to obtain CD25+CD127 Treg
and CD25CD127+ T naive cells. To determine Treg-mediated Th1 or Th2
cell response, sorted Treg cells preloaded with CFSE were cocultured with T
naive cells at 1:1 ratio for 72 hr in the presence of neutralizing IL-10 or TGF-
b antibody (Santa Cruz). The respective Th1 and Th2 cell-associated cytokine
positivity (in CFSE-negative population) was then analyzed flow cytometrically.
Site-Directed Mutagenesis, cDNA, and Transfection
Specifications of wild-type and mutant plasmid constructs used to identify
STAT3-FoxP3 interaction are as follows. FOXP3WT (wild-type FoxP3),
FOXP3DN (N-terminal deleted FoxP3), and FOXP3WWRR (point mutations atunity 39, 1057–1069, December 12, 2013 ª2013 Elsevier Inc. 1067
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clones were obtained from A. Rao (Wu et al., 2006). FOXP3D250/251 (deletion
mutation of amino acids 250 and 251 at ZnF domain), FOXP3C204S (point
mutation at Zip domain), FOXP3P72M, FOXP3T73V, FOXP3K85E, FOXP3P88M,
FOXP3P90M, and FOXP3H91F (point mutations at ex-2 domain) clones were
generated through site-directed mutagenesis from FOXP3WT. FOXP3DEX2
(exon 2 deletion clone that inhibits interaction of FoxP3 with RORgt),
FOXP3DZNF (zinc finger motif deletion clone), FOXP3DZIP (leucine zipper motif
deletion clone), FOXP3DFKH (FKH motif deletion clone that will not translocate
to nucleus and will not bind DNA), and FOXP3DFKH+NLS (FOXP3DFKH clone with
nuclear localization signal that will translocate to nucleus but will not bind DNA)
clones were received from S. Hori (Hori et al., 2003). Wild-type (STAT3WT) and
N-terminal-truncated (STAT3DN) STAT3 clones were obtained from L. Cheng.
FoxP3 clones were made resistant to shRNA (FOXP3shRNAmt) by site-directed
mutagenesis at ex-4 (bases T730C, G736A, C741T, which give rise to wild-
type protein but shRNA-insensitive mRNA).
T cells were transduced with lentil viral FoxP3, STAT3, or STAT5 shRNA
(Open Biosystem). T cells were transfected with wild-type or mutant FoxP3
or STAT3 clones, FoxP3, STAT3, HAT1, p300, or control-siRNA (Dharmacon)
and FoxP3 or STAT3-decoy oligonucleotide (Hysel India) by electroporation
using a single-pulse protocol (BTX Electro porator). Under these conditions
we consistently reached a transfection efficiency of 85%–90% without reduc-
tion of viability of cells. Protein andmRNA amounts were determined by immu-
noblot and qPCR respectively.
Immunoblot, Imaging, and Chromatin Immunoprecipitation
A total of 50 mg of nuclear extract was used for immunoblot with specific anti-
bodies (Santa Cruz). For the determination of direct interaction between two
proteins, coimmunoprecipitation and immunoblot techniques were employed.
Cytokine release was quantified by ELISA (BD PharMingen). For confocal
imaging, purified normal T cells and Treg cells were allowed to adhere to
poly-L-lysine-coated slides and labeled with fluorescent-tagged antibodies.
Nuclei were labeled with 4,6-diamidino-2-phenylindole (DAPI). Cells were
imaged with Zeiss inverted confocal microscope.
ChIP assays were carried out with a ChIP assay kit (Millipore) according to a
modification of the manufacturer’s instructions. A total of 2 3 106 cells were
fixed and protein-DNA complexes were cross-linked and sonicated to shear
the DNA. The cell supernatants were incubated with RNA Pol-II, FoxP3,
STAT3, HAT1, or Ac-Histones antibodies and the Ab-protein-DNA complexes
were purified with protein A-agarose. Chromatin complexes were reverse
cross-linked at 65C and DNA was recovered. For ChIP-re-ChIP assay, the
first round of immunoprecipitates were subjected to another round of immuno-
precipitation with a second antibody. DNA fragments were amplified by qPCR
with specific primers (Table S1).
2D Gel Electrophoresis and MALDI TOF MS
Immunopurified FoxP3-associated proteins were isoelectric-focused in
PROTEAN IEF Cell with pH 3–10 IPG strip followed by a 2D gel electrophoresis
with 8% SDS-PAGE in a PROTEAN II xi system (Bio-Rad). The gel was stained
and protein spots were digestedwith trypsin. An aliquot of 1.5 ml peptide digest
was mixed with equal amount of a-cyano-4-hydroxycinnamic acid matrix
solution. Mass spectra were obtained on an Autoflex-II MALDI TOF TOF
mass spectrometer equipped with a pulsed N2 laser (l = 337 nm). Peptide
monoisotopic signals were processed in FlexAnalysis software (Bruker Dalton-
ics). The processed peaks were analyzed in MASCOT (Matrix Science) for
protein identification. The significance threshold was set to a minimum of
95% (p% 0.05).
Structural Analysis
The interaction model for dimeric FoxP3 and STAT3 were derived with Z-Dock
(v.3.0.2) (Pierce et al., 2011). The required coordinates for the proteins were
obtained from Protein Data Bank accession numbers 1BG1 (STAT3-DNA
complex), 3QRF (FoxP3 dimer), and 2P0W (HAT1) (Becker et al., 1998; Ban-
dukwala et al., 2011). The structural coordinates were processed in the protein
preparation wizard (Schrodinger Suite). All the missing hydrogen atoms were
added and the crystallographic water molecules were removed. The pro-
cessed 3D structures were subjected to energy minimized with OPLS-2005
force field (Jorgensen and Tirado-Rives, 1988). The interacting models were1068 Immunity 39, 1057–1069, December 12, 2013 ª2013 Elsevier Inpredicted by the fast Fourier transform implemented in Z-dock that allows
3D searches of spatial degrees of freedom between macromolecules (Mintse-
ris et al., 2007). The resulting interacting models were again subjected to mini-
mization and were visualized with PyMOL (Schrodinger).
Statistical Analysis
Values are shown as standard error of mean (SEM) except where otherwise
indicated. Comparison of multiple experimental groups was performed by
2-way ANOVA followed by a post-hoc Bonferroni modification of multiple
comparison t test. Data were analyzed and, when appropriate, significance
of the differences between mean values was determined by a Student’s
t test. Results were considered significant at p% 0.05.SUPPLEMENTAL INFORMATION
Supplemental Information includes three figures and one table and can
be found with this article online at http://dx.doi.org/10.1016/j.immuni.2013.
11.005.
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